| Dr Eli D Musselman, MD | |
|
1111 Duff Avenue, Ames, IA 50010-3014 | |
| (515) 239-2151 | |
| (515) 239-2057 |
| Full Name | Dr Eli D Musselman |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 9 Years |
| Location | 1111 Duff Avenue, Ames, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053791251 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | R-10277 (Iowa) | Secondary |
| 207L00000X | Anesthesiology | MD-45977 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Greeley Medical Center | Ames, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mcfarland Clinic Pc | 1254244239 | 320 |
News Archive
Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.
Celebrating its fifth year on CAN-TV, SAVE THE PATIENT is hosting a special community health show to reinforce the importance of positive, proactive and "preventative" interactions between patients and their health care resources—ranging from physicians to surgeons, nurses to advocates, pharmacists to educators, clinics to hospitals.
Adaptimmune Therapeutics plc, a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 percent of lung cancers.
The Houston Emergency Response Opioid Engagement System was recently awarded two grants that will help fund the opioid intervention program through the end of 2020.
› Verified 6 days ago
| Entity Name | Mcfarland Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639135643 PECOS PAC ID: 1254244239 Enrollment ID: O20031106000338 |
News Archive
Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.
Celebrating its fifth year on CAN-TV, SAVE THE PATIENT is hosting a special community health show to reinforce the importance of positive, proactive and "preventative" interactions between patients and their health care resources—ranging from physicians to surgeons, nurses to advocates, pharmacists to educators, clinics to hospitals.
Adaptimmune Therapeutics plc, a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 percent of lung cancers.
The Houston Emergency Response Opioid Engagement System was recently awarded two grants that will help fund the opioid intervention program through the end of 2020.
› Verified 6 days ago
| Entity Name | Iowa Physicians Clinic Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366425274 PECOS PAC ID: 8729992318 Enrollment ID: O20031118000363 |
News Archive
Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.
Celebrating its fifth year on CAN-TV, SAVE THE PATIENT is hosting a special community health show to reinforce the importance of positive, proactive and "preventative" interactions between patients and their health care resources—ranging from physicians to surgeons, nurses to advocates, pharmacists to educators, clinics to hospitals.
Adaptimmune Therapeutics plc, a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 percent of lung cancers.
The Houston Emergency Response Opioid Engagement System was recently awarded two grants that will help fund the opioid intervention program through the end of 2020.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eli D Musselman, MD 1215 Duff Avenue, Ames, IA 50010-3014 Ph: (515) 239-2151 | Dr Eli D Musselman, MD 1111 Duff Avenue, Ames, IA 50010-3014 Ph: (515) 239-2151 |
News Archive
Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.
Celebrating its fifth year on CAN-TV, SAVE THE PATIENT is hosting a special community health show to reinforce the importance of positive, proactive and "preventative" interactions between patients and their health care resources—ranging from physicians to surgeons, nurses to advocates, pharmacists to educators, clinics to hospitals.
Adaptimmune Therapeutics plc, a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 percent of lung cancers.
The Houston Emergency Response Opioid Engagement System was recently awarded two grants that will help fund the opioid intervention program through the end of 2020.
› Verified 6 days ago
Jeffrey A. Drawbond, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-2182 Fax: 515-239-3665 | |
Dr. Matthew Ryan Okland, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Duff Avenue, Mcfarland Clinic Pc, Ames, IA 50010 Phone: 515-239-2182 Fax: 515-239-3665 | |
Dr. Lois Y. Stoltze, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-2182 Fax: 515-239-3665 | |
Dr. Gregory R. Utesch, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-2182 Fax: 515-239-3665 | |
Dr. Grant Henry Young, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-2151 | |
Dr. Brenda J. Kruse, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-2182 Fax: 515-239-3665 |